IO-106 / Immune-Onc Therap - LARVOL DELTA

Novel Myeloid Checkpoint Inhibitors Targeting the LILRB (ILT) Family Members (PEGS 2023) - "These include IO-108, an antagonist antibody targeting LILRB2 (ILT4), in Phase I clinical development for solid tumors and IO-202; an antagonist antibody targeting LILRB4 (ILT3), in Phase I clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class antagonist antibody targeting LAIR1; IO-312, a novel bispecific antibody targeting LILRB4 and CD3 (LILRB4 x CD3); and multiple undisclosed programs."

Checkpoint inhibition • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • LAIR1 • LILRB4

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1 (Businesswire) - "Immune-Onc Therapeutics...announced the selection of IO-106, a first-in-class myeloid and stromal checkpoint inhibitor targeting the inhibitory receptor, Leukocyte-Associated Immunoglobulin-Like Receptor 1 (LAIR1), for clinical development. The Company will present a scientific poster on the therapeutic potential of anti-LAIR1 antibodies at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop on April 21st in San Diego, CA."

Pipeline update • Preclinical • Oncology